Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

This is written in the approval document as:

Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

Citation

R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6510/506_v4_R-Gem_OX.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) CD20 + Diffuse Large B-Cell Lymphoma Gemcitabine, Oxaliplatin, Rituximab
HSE (1) CD20 + Non-Hodgkin Lymphoma Gemcitabine, Oxaliplatin, Rituximab